ArticleClinical case reports2025
Case Report: Hemorrhagic Vasculitis in a Patient With Multiple Sclerosis Receiving Fingolimod.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Hemorrhagic Vasculitis in a Patient With Multiple Sclerosis Receiving Fingolimod.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fingolimod is an effective therapy for relapsing-remitting multiple sclerosis (RRMS) but predisposes patients to opportunistic infections, including varicella-zoster virus (VZV). We report a case of a 27-year-old Iranian man with a history of MS, stable on fingolimod for two years, who presented with worsening paresthesia and headache. His condition acutely deteriorated, leading to a diagnosis of VZV-associated cerebral vasculitis, intracerebral hemorrhage, and myelitis, confirmed via cerebrospinal fluid PCR and angiography. This case underscores that patients on fingolimod can develop severe, atypical neurological complications from VZV reactivation, even in the absence of cutaneous signs. A high index of suspicion and prompt diagnostic workup are crucial for early antiviral and immunomodulatory treatment to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.